Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. - Wikidata - awgldk - TriplyDB

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

http://www.wikidata.org/entity/Q38110227

about

[Intracellular targets : current data on effectiveness and safety profile].Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.Selective JAK inhibitors in development for rheumatoid arthritis.Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.p38 MAPK inhibitors: a patent review (2012 - 2013).Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects.Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155.Tofacitinib: A Review in Rheumatoid Arthritis.[Update on kinase inhibitors].

P2860

Q30689247-89BEE95D-BE09-4EF8-A5BB-84DB4C4A6948 Q33854992-7C9D5473-10E8-49E4-B9FB-956D8DB79327 Q33932779-CE66A1B5-36D1-4F82-BF94-502917AD1EBF Q34419615-D5509C18-E8CD-4AB4-8365-B9C406417B98 Q35884253-192565F1-1C95-4B33-9C15-542593F04416 Q38194600-D3F8B14F-BF25-4A10-A97E-A9479E986802 Q38210286-C63BD467-1732-4D01-9E1D-EE3736881ABA Q38543383-77FDFADC-2657-4554-8BF2-819723E3CA08 Q38744431-068B4261-D26F-4247-A796-EC23DAC12E3B Q38855013-514680BE-EEE3-4692-9C32-DEECD48F8721 Q38924086-4BC0A88E-DF84-4571-9DBA-F101DE728007 Q38932097-DA753062-36C1-4EAC-A97D-F87849DDF8E9 Q42574067-FCCAF180-50AE-49EB-A509-96242A2AF218 Q43280727-E6A09C21-E6E2-4EE9-B49F-39DD91B371F3 Q52850373-B36D9472-212E-4ECD-8EA4-5924B67D99F4

P2860

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

http://www.wikidata.org/entity/Q38110227

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

@en

type

label

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

@en

prefLabel

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

@en

P1433

Q38110227-3E8EB9C9-F482-4789-87EE-B94C8FED83F7

P1476

Q38110227-CAB5A2EB-9545-4A5D-9655-3C76ECD2E23F

P2860

Q38110227-10099BCE-13B6-405B-9EB2-B818A20D7B22

Q38110227-1221EFFB-5409-492A-A663-65F81BAF82B4

Q38110227-141F29E0-D680-484D-81F6-E8B36CCA7014

Q38110227-17E1B78B-C2E6-4A09-9C42-377D8939029D

Q38110227-21821836-AF14-490F-99BB-36F604BC93C6

Q38110227-224B199C-9A1B-4A92-BCE0-E51275016AE5

Q38110227-23506D77-9265-429D-A139-A4A815754382

Q38110227-467A11C5-2FC6-4A88-9570-032882F147B6

Q38110227-4B7AB3BB-0759-459A-A3CE-3D859B0F11D9

Q38110227-4D4D720A-D34B-48C7-BD40-0079D69AA986

P2888

Q38110227-9393692D-B7F7-4087-9B74-D174897C06D2

P304

Q38110227-7527D431-5830-49E0-A54E-8724CACF4985

P31

Q38110227-532B9ABF-8402-4287-9C19-B17044E9BDC8

P356

Q38110227-5B49C92B-D81E-479A-B71F-2CD7C888F299

P433

Q38110227-BC5C44DF-EFE9-46E2-9D0A-4BFCF9FD500C

P478

Q38110227-B910F87B-FA9A-401D-BF33-765475C55701

P50

Q38110227-9AFFB571-F269-475E-896A-79D47787A19B

P577

Q38110227-C03F9075-AFB8-43A9-A2DF-EB123229BC66

P5875

Q38110227-2C105722-DD11-45F6-9BD9-1091048BAFAE

P6179

Q38110227-0078380F-8310-45DA-BB0C-EA97FFC748CB

P698

Q38110227-730FFBCD-EC31-4456-ABF3-3D5769C8319C

P356

S40265-013-0065-8

P1433

P1476

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

@en

P2860

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Biologic agents in rheumatoid arthritis: an update for managed care professionals

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

A quantitative analysis of kinase inhibitor selectivity

The pathogenesis of rheumatoid arthritis

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

P2888

s40265-013-0065-8

P304

857-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-013-0065-8

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236958277

http://www.w3.org/2001/XMLSchema#string

P6179

1028330323

http://www.w3.org/2001/XMLSchema#string

P698

23716132

http://www.w3.org/2001/XMLSchema#string